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Abstract
Background: Health technology assessments (HTAs) by the National Institute for Health and
Clinical Excellence (NICE) enjoy high levels of international attention. The present analysis
addresses NICE's appraisal of methylphenidate, atomoxetine and dexamphetamine for attention-
deficit/hyperactivity disorder (ADHD) in children and adolescents, published in March 2006.
Methods: A qualitative study of NICE Technology Appraisal No. 98 was done focusing on the
>600-page technology assessment report, which aimed at evaluating ADHD treatment strategies
by a clinical effectiveness review and an economic analysis using meta-analytical techniques and a
cost-effectiveness model.
Results: The technology assessment was unable to differentiate between the various drugs in
terms of efficacy, and its economic model was ultimately driven by cost differences. While the
assessment concluded that the economic model "clearly identified an optimal treatment strategy"
with first-line dexamphetamine, the NICE appraisal committee subsequently found it impossible to
distinguish between the different strategies on grounds of cost-effectiveness. Analyzing the
assessment reveals gaps and inconsistencies concerning data selection (ultimately relying on a small
number of short-term studies only), data synthesis (pooling of heterogeneous study designs and
clinical endpoints), and economic model structure (identifying double-counting of nonresponders
as a likely source of bias, alongside further methodological anomalies).
Conclusion: Many conclusions of the NICE technology assessment rest on shaky grounds. There
remains a need for a new, state-of-the-art systematic review of ADHD treatment strategies
including economic evaluation, which ideally should address outcomes beyond children's health-
related quality of life, such as long-term sequelae of the disorder and caregiver burden.
Background
Health care policy makers and clinicians increasingly seek
evidence-based guidance on how to provide mental
health services effectively and efficiently. Systematic
reviews have come to be accepted to produce the best esti-
mates of clinical efficacy and effectiveness, thus constitut-
ing a cornerstone of policy analysis and cost-effectiveness
evaluation [1]. Founded in 1999, the London-based
National Institute for Health and Clinical Excellence
(NICE) has quickly established itself as a leading agency
conducting health technology assessments (HTAs) includ-
ing economic evaluation. A review team of the World
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Health Organization observed that its "published tech-
nology appraisals are already being used as international
benchmarks" [2], beyond NICE's primary remit to pro-
vide guidance for the National Health Service in England
and Wales.
In March 2006, NICE published guidance on the use of
methylphenidate, atomoxetine and dexamphetamine for
attention-deficit/hyperactivity disorder (ADHD) in chil-
dren and adolescents (NICE Technology Appraisal No. 98
[3]). This guidance was based on a >600-page technology
assessment report, which had been produced by a team of
ten experts, including one clinical specialist who provided
input and comments [4].
In the United States, NICE guidelines are routinely refer-
enced by the National Guideline Clearinghouse, an initi-
ative of the Agency for Healthcare Research and Quality
(AHRQ). NICE technology assessments and appraisals are
easily accessible through its website, which receives more
than one million hits per month from the United States
alone [5]. The NICE assessment of ADHD treatment strat-
egies thus might have great influence on future treatment
practices beyond England and Wales, notably including
the United States where ADHD now is the most com-
monly diagnosed behavioral disorder in children, with
approximately 4.4 million diagnosed and 2.5 million tak-
ing medication for the disorder in the age group 4 – 17
years [6]. Therefore a critical appraisal of NICE Technol-
ogy Appraisal No. 98 will be of interest to mental health
care policy makers and clinicians.
Methods
A qualitative study was done of NICE Technology
Appraisal No. 98, "Methylphenidate, atomoxetine and
dexamfetamine for attention deficit hyperactivity disorder
(ADHD) in children and adolescents (Review of Technol-
ogy Appraisal 13)" [3]. The study focused on policy-rele-
vant aspects and had descriptive, explorative, and
explanatory elements.
Its initial phase consisted of defining a theoretical frame-
work for analysis. This included a description of NICE
technology appraisal processes, which fell in a period of
substantial upgrade and definition of "reference case"
analysis by NICE [7,8]. During this phase, a thematic
framework was defined, comprising use of the "accounta-
bility for reasonableness" concept as a process benchmark
[9,10], a critique of the technology assessment report
underlying the appraisal, as well as a review of the clinical
and economic literature on attention-deficit/hyperactivity
disorder [11].
Its second phase comprised data collection employing a
number of closely related strategies, including retrieval
and analysis of documents related to the ADHD appraisal
which were posted on the NICE website. Scientific articles
cited in these documents were obtained for analysis. This
was supplemented by literature searches (using the
PubMed and, via EBSCO host services, the Business
Source Elite databases as well as Google Scholar) for arti-
cles on ADHD diagnosis, treatment, compliance, cost, and
cost-effectiveness, which were complemented by a search
for relevant abstracts presented at international meetings
in the fields of psychiatry and health economics. Docu-
ments were indexed using categories including study type,
product tested, and subject matter (e.g., "treatment com-
pliance") for further analysis and interpretation.
The analysis reported here is part of this more comprehen-
sive study of NICE appraisal processes by the same author
[11], and it is focused on the underlying Technology
Assessment Report [4]. The purpose of the present paper
is to shed light on the validity of the conclusions offered
by NICE; it should be emphasized that it is not intended
to assign responsibility for any identified problems to par-
ticular actors (such as NICE, its committees, or the assess-
ment team). Unless specified otherwise, the following
citations will refer to the Technology Assessment Report
("TAR" [4]), which was subsequently published as a full
paper in the Health Technology Assessment monograph
series of the NHS R&D HTA Programme [12], apparently
unchanged.
Results
The various products evaluated by NICE are summarized
in Table 1. The scope of the assessment [13] and its final
protocol [14] specified that these products should be
compared to placebo and usual care. Outcomes should
include the incidence and severity of core symptoms,
problem behaviors, educational performance, measures
of depression and/or anxiety, measures of conduct/oppo-
sitional-defiant-disorder-related outcomes, adverse
events, and quality of life. A recommendation was also
included to consider the impact of co-morbid disorders,
quality of life of family members, and optimal duration of
treatment, "where the evidence permits". The scope effec-
tively excluded an evaluation of non-drug treatment and
of ADHD in adults. Also alternative treatments were not
reviewed [15].
The Technology Assessment Report (TAR), comprising
605 pages with 13 appendices, included a systematic
review of the evidence and a statistical data synthesis
using mixed treatment comparison (MTC) techniques, a
review of submissions by manufacturers, and an eco-
nomic evaluation model. Main conclusions of the TAR
were that "(i) drug therapy seems to be superior to no
drug therapy; (ii) no significant differences between the
various drugs in terms of efficacy or side effects wereChild and Adolescent Psychiatry and Mental Health 2008, 2:1 http://www.capmh.com/content/2/1/1
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found – mainly due to lack of evidence; (iii) the additional
benefits from behavioural therapy (in combination with
drug therapy) are uncertain" and: "Given the lack of evi-
dence for any differences in effectiveness between the
drugs, the [economic] model tends to be driven by drug
cost, which differ considerably" (TAR, p. 20). More specif-
ically, it was asserted that "for a decision taken now, with
current available data, the results of the economic model
clearly identify an optimal treatment strategy" (TAR, p. 261;
italics added) and that "this analysis showed that a treat-
ment strategy of 1st line dexamphetamine, followed by
2nd line methylphenidate immediate-release for treat-
ment failures, followed by 3rd line atomoxetine for repeat
treatment failures was optimal" (TAR, p. 260).
Remarkably the NICE Appraisal Committee did not
uphold these "clear conclusions", issuing guidance that
was based on the assumption that it was "not possible to
distinguish between the different [treatment] strategies on
the grounds of cost-effectiveness" [3].
Analysis of the TAR reveals a number of methodological
issues, which collectively leave the assessment open to cri-
tique concerning all four essential components of a review
question [16], namely the population studied (e.g., exclu-
sion of adults and failure to address the impact of coexist-
ing conditions), the choice of interventions (e.g.,
exclusion of psychosocial treatment), the clinical and eco-
nomic outcomes criteria used, as well as the study designs
and selection criteria. The following critique will concen-
trate on key issues concerning data selection and synthesis
as well as the model developed for economic evaluation.
Data selection for assessment
Departing from the assessment protocol [14], literature
searches for assessment did not include "abstracts, ... con-
ference proceedings, ... and other grey literature etc." (see
final protocol, pp. 2f. [14]; cf. also TAR, p. 178), thus
excluding relevant cost-effectiveness analyses in the public
domain at the time of assessment [17-20]. This notwith-
standing, it was claimed that "this review presents a com-
prehensive overview of existing economic evaluations of
methylphenidate, atomoxetine and dexamphetamine for
children and adolescents with ADHD" (TAR, p. 266). Fur-
ther search anomalies include the overlooking of at least
two clinical studies meeting the specified inclusion crite-
ria [21,22].
For assessment, studies had to have a minimum duration
of three weeks because "the literature suggests that three
weeks is the minimum duration for therapeutic trials" to
assess "the impact on the social adjustment of the child"
(TAR, p. 44), citing the DSM-IV diagnostic manual (TAR,
p. 45). The rationale offered was that "the effect of medi-
cation on behaviour is often (not always) apparent imme-
diately, but the impact on the social adjustment of the
child my well not be apparent in the first days of therapy
(final assessment protocol [14], pp. 3ff., and TAR, p. 45).
To make sense out of this reasoning, one would expect a
minimum treatment duration of three weeks. However, a
minimum study duration of three weeks was applied as
inclusion criterion. As a consequence, more than one
third of the 64 trials included in the clinical effectiveness
review were very-short-term crossover studies with treat-
ment periods of one week or less, some of which had been
conducted without washout phases between treatment
periods (TAR, pp. 51–163) [11].
The observation that the choice of outcomes measures
reflects a critical design choice for analysis (TAR, p. 178)
was not followed by a review of the literature on measure-
ment instruments [23,24]. Although social adjustment of
patients was implied to be the outcome of interest (TAR,
p. 45), clinical effect measures reflecting functional
impairment were discarded from analysis (TAR, p. 46).
Instead, clinical global impressions (CGI scores) were
used "as a proxy of quality of life" (TAR, pp. 16 and 48),
and CGI-I (improvement) subscores were selected as the
primary endpoint informing economic evaluation. In this
respect, the economic analysis deviated from the clinical
effectiveness review that had included measures of hyper-
activity and comprised a total of 64 randomized clinical
Table 1: Products evaluated by NICE
Trade Name 
(England)
Active Ingredient Formulation Cost/Daily Dose1 Assumed Total 
Daily Dose
Daily Dosage 
Schedule
Dexedrine Dex amphetamine Short-acting  0.43 20 mg/d 2 (-3) times
Ritalin Methyl phenidate Short-acting  0.56 30 mg/d 3 (2–4) times
Equasym Methyl phenidate Short-acting  0.53 30 mg/d 3 (2–4) times
Concerta XL Methyl phenidate Long-acting (~12 h)  1.23 36 mg/d 1 time
Equasym XL Methyl phenidate Long-acting (~8 h)  1.17 30 mg/d 1 time
Strattera Atomoxetine Long-acting  1.95 Irrelevant (flat pricing) 1 (-2) times
1Acquisition costs of the National Health Service (NHS) in England (net prices, excluding VAT and not accounting for negotiated procurement 
discounts in some settings), from British National Formulary 51, March 2006; note that individual doses and thus costs may vary. Assumed average 
doses should not be confused with dose recommendations.Child and Adolescent Psychiatry and Mental Health 2008, 2:1 http://www.capmh.com/content/2/1/1
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trials (RCTs) plus the MTA study [25,26]. This decision
was motivated by the desire to compute quality-adjusted
life years (QALYs) as effectiveness measure for economic
modeling (TAR, pp. 224f.). Since this maneuver left only
five RCTs with treatment durations from three to eight
weeks for modeling, and none of those included dexam-
phetamine, a study previously excluded for inadequate
data presentation was secondarily added in order to have
any data on dexamphetamine for economic analysis (TAR,
pp. 225f. and p. 338). Given well-documented gender dif-
ferences in ADHD [27], which include clinical response to
methylphenidate [28], and the fact that the disorder is
most often diagnosed in boys [29], it is noteworthy that
this three-weeks cross-over study had reported on 32 girls
[30]. The assessment did not offer a discussion of this
peculiarity. On this basis, after eliminating consideration
of the role of concomitant psychosocial interventions, 19
alternative treatment "strategies" (in fact, product
sequences) were modeled (TAR, p. 221).
Another important gap occurred in relation to atomoxet-
ine. First, one out of two state-of-the-art RCTs comparing
atomoxetine and long-acting methylphenidate was over-
looked [22,31]. These studies concurred suggesting lower
or at best equal efficacy of atomoxetine [22,31-33]. Sec-
ond, two analyses were not considered that provided
effect size estimates for long-acting stimulants (0.95 –
1.02) and nonstimulant medications (0.44 – 0.62), using
core symptom improvement as effect measure [34-37].
These findings had been interpreted by their authors as
"substantial and significant differences in efficacy" [37].
Data synthesis
In an attempt to overcome the limitations of the remain-
ing database, the NICE assessment relied on advanced
mixed-treatment comparison techniques for quantitative
meta-analysis of response rates, which were subsequently
transformed into QALY gains. For QALY computation,
quality weights were derived from utility studies that had
used health state descriptions, which did neither corre-
spond to the CGI criteria nor to any of the other clinical
endpoints secondarily added (cf. TAR, pp. 359ff.). This
approach was pursued despite explicit recognition that
"the validity of these measures depends on the content
and style of the vignette used to describe each health state"
(TAR, p. 181).
In order to broaden the database of six RCTs, data derived
from different clinical effect measures were subsequently
pooled for "sensitivity analyses"; data synthesis com-
prised heterogeneously defined "response rates" based on
(in addition to the CGI-I subscores) CGI-S ratings as well
SNAP-IV and ADHD-RS scores (TAR, p. 254), while the
most widely used measures of clinical efficacy in ADHD
trials, the Conners Rating Scales [23,24], remained
excluded from economic modeling (TAR, p. 224) despite
their well-documented psychometric properties [24].
These narrow-band symptom scales (i.e., the SNAP-IV and
ADHD-RS [23,24]) were erroneously regarded as "disease-
specific instruments [measuring] health-related quality of
life in children" (TAR, p. 176). In total, these secondary
extensions resulted in the inclusion of 13 RCTs, four of
which were designated "commercial-in-confidence" and
not disclosed (TAR, Chapter 6).
In a final step, also the MTA study [25,26] – arguably the
most important clinical study completed in ADHD to date
– was added, although it remains enigmatic which data
were actually used, as the model used information from
three out of the four study arms only (TAR, p. 254):
Whereas it was stated that "the nature of the treatment
received in the community comparison arm of the MTA
trial is still unclear, and as a result this data is omitted
from the analysis" (TAR, p. 254), a table on the same page
of the assessment report explicates that "results for behav-
ioral treatment were omitted as not relevant to this
review" (TAR, p. 254).
Whereas the assessment team did not explain its implicit
assumption that CGI-I subscores – its primary measure of
effectiveness used for the calculation of "response rates",
which directly refers to a comparison "to the patient's con-
dition before admission to the project" [38] – were inde-
pendent from baseline, it rejected the Conners Rating
Scales – the most widely used group of measurement
instruments in ADHD studies [24] – for precisely this rea-
son (TAR, p. 186 and p. 224). As a consequence, (apart
from the enigmatic use of MTA study data) none of the 14
extended treatment studies reviewed by Schachar et al.
(2002) [39] were included in data synthesis for cost-effec-
tiveness evaluation (cf. TAR, Chapter 6). Also insights
from an important 24-months RCT involving more than
100 patients treated with methylphenidate [40,41] were
not considered because the study did not fit the narrowly
defined inclusion criteria for review. Finally, discussion in
the assessment report of the 24-months follow-up data
from the MTA study, providing insights into the persist-
ence of treatment effects over the first ten months after
trial completion [42], was limited to the clinical review
(TAR, p. 168); these data were not addressed in the con-
text of the economic modeling exercise (TAR, Chapter 6).
Although the assessment group correctly observed that
MTA subgroup analyses "should be seen as 'exploratory',
because of the danger of repeated statistical testing with a
sample not designed for this purpose" (TAR, p. 167), it
claimed at the same time that its own "model is probabi-
listic, meaning that relevant input parameters are entered
as probabilistic distributions in order to represent the
uncertainty around each point estimate" (TAR, p. 220),Child and Adolescent Psychiatry and Mental Health 2008, 2:1 http://www.capmh.com/content/2/1/1
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emphasizing that "the output from the model incorpo-
rates the uncertainty around the estimated response rates"
(TAR, p. 229). However, in RCTs it is the primary analysis,
as defined ex ante, which is most important, and the CGI
scores did not represent the primary endpoint in any of
the studies selected for synthesis. While it is certainly legit-
imate to carry out secondary analyses, these should not be
represented as fully capturing stochastic uncertainty [43].
So-derived differences in QALYs gained by each treatment
"strategy" extended to the third or fourth decimal place
only (TAR, pp. 237ff.), and the primary analysis produced
a series of inconsistent rankings (TAR, p. 237), which were
left uncommented and disappeared only after secondary
model extensions ("sensitivity analyses", TAR, pp. 240ff.)
comprising the pooling of heterogeneous response crite-
ria mentioned earlier. Although it was claimed that "the
issue of heterogeneity was overcome by basing the base
case [primary] analysis on trials that are more similar in
terms of how they measure the outcome of interest" (TAR,
p. 266), in fact internally consistent model results were
achieved after this pooling only, and there is no indica-
tion that potential confounding effects between treatment
strategies and effect measures were assessed.
Efficacy versus effectiveness
An important issue pervading the NICE assessment is the
way the distinction between efficacy and effectiveness was
(not) addressed. Whereas RCTs follow an explanatory ori-
entation ("Can the intervention work?"), economic evalu-
ations to be meaningful require a pragmatic orientation
("Does the intervention work?") [16,44,45]. Efficacy data
collected during RCTs deliberately and necessarily exclude
naturalistic effects associated with a routine clinical prac-
tice setting, while effectiveness may be influenced by a
number of external factors, notably including poor treat-
ment compliance. "Artificially enhanced compliance" in
RCTs has come to be recognized as a major threat to their
external validity [46]. This is a relevant aspect since the
more expensive treatment options evaluated (atomoxet-
ine and modified-release formulations of methylpheni-
date) differ from their comparators by their simplified
dosage regimens, which may be expected to result in
improved treatment adherence in practice settings.
There are multiple streams of evidence supporting this
expectation. First, there is a statistically significant associ-
ation between complexity of dosage regimens and treat-
ment compliance [47]. Second, there are reasons to
assume that treatment adherence of patients with ADHD
may be impaired by disease-specific factors [48,49]. Third,
due to their pharmacokinetic and pharmacodynamic
properties, the behavioral effects of short-acting stimu-
lants dissipate rapidly after three to four hours – making
these drugs prototypical examples of non-forgiving com-
pounds regarding noncompliance [50-55]. Fourth, three
independent retrospective database studies consistently
indicate higher treatment persistence rates for patients
receiving long-acting stimulants compared to short-acting
formulations [56-60]. Although analyses based on admin-
istrative data typically do not allow differential analysis of
reasons for treatment discontinuation and may be dis-
torted by patient selection bias, data showing a higher
number of prior diagnoses and significantly lower rates of
accidents, injuries, emergency room visits, and hospitali-
zations among those treated with long-acting formula-
tions are consistent with the assumption that such
distortions were absent [56,59,60]. Fifth, mediator analy-
ses of the NIMH MTA study confirm the important role of
compliance: as intended acceptance/attendance was
found to significantly enhance treatment response for
both the medication management and combined treat-
ment strategies [26]. The NICE assessment group over-
looked these findings (TAR, pp. 167ff.) and reasoned
instead that "we can also incorporate the results of the
MTA trial, but only by assuming that the medical manage-
ment group in that trial represents treatment with imme-
diate-release methylphenidate" (TAR, p. 253).
For economic evaluation, there are two broadly accepted
ways to address the impact of compliance [61,62], i.e., the
use of decision analytic models combined with appropri-
ate sensitivity analyses and information from randomized
"pragmatic trials" with minimal study management [63].
Modeling studies, sixth, have been indicative of an accept-
able cost-effectiveness of long-acting methylphenidate,
possibly reaching extending dominance over short-acting
formulations [17,18,64]. Seventh, a randomized open-
label study comparing long-acting with short-acting
methylphenidate reported a number-needed-to-treat
(NNT) of 3.6 to 4.8 to achieve one additional responder
(depending on response criterion applied), consistently
below the NNTs synthesized for assessment (TAR, pp.
226ff.) [11,65,66], although this particular study was
impaired by the absence of teacher-reported outcome rat-
ings.
None of these aspects are reflected in the NICE assess-
ment. Instead it was "assumed that the trial data [referring
to double-blind, double-dummy ADHD trials] ade-
quately captures the effect of compliance on response to
treatment" (TAR, p. 232). As a consequence, data from
highly controlled double-blind RCTs and from rand-
omized pragmatic open-label studies were pooled, neces-
sarily concealing any differentiation on grounds of
treatment compliance. Nevertheless it was claimed "the
effect of compliance on response rates [...] is reflected in
the model" (TAR, p. 250).Child and Adolescent Psychiatry and Mental Health 2008, 2:1 http://www.capmh.com/content/2/1/1
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Economic model
The economic model (cf. Fig. 1) relied on cost per QALY
estimates based on response rates, using utility weights
taken from one study reporting parent-proxy ratings using
the EQ-5D [67] but not from standard gamble experi-
ments as stated in the assessment report (TAR, p. 235).
Although the structure of the model implied assumptions
on withdrawal rates, which caused double-counting of
nonresponders (TAR, p. 230), no attention was paid to
the uneven effect this modeling approach had on the
treatment options evaluated: the fact that for dexamphet-
amine extremely low withdrawal rates were assumed
(TAR, p. 236, solely based on the study by Sharp et al.,
1999 [30], with n = 32 girls observed over three weeks,
which had initially been excluded: TAR, p. 231; cf. also
TAR, pp. 225f. and p. 338) could only bias the modeled
"treatment continuation rates" (cf. TAR, p. 222f.) in favor
of dexamphetamine. This source of bias remained
unmentioned.
None of the studies selected for the primary model
exceeded an observation period of eight weeks per treat-
ment arm (TAR, p. 226), and also the secondary model
extensions (referred to as "sensitivity analyses") were
informed by trials with observations periods of 12 weeks
or less, except for the data extracted from three out of four
parallel arms of the MTA study (TAR, p. 254). On this
basis, costs and benefits were extrapolated over a time
horizon of 12 years. Although the assessment includes a
discussion of sensitivity of findings to time horizon (TAR,
pp. 245ff.), this did not include a review of long-term
sequelae associated with ADHD. No attempt was made to
address the impact of the disorder on educational out-
comes, injuries and accidents, or other problems such as
encounters with the criminal justice system and the bur-
den of caregivers.
The technology assessment purports to have "clearly iden-
tified an optimal treatment strategy" (TAR, pp. 19, 261,
266). The caveats offered essentially relate to a paucity of
evidence and poor reporting of studies (e.g., TAR, pp.
18ff., 266), which were blamed for the inability to dis-
criminate between drugs in efficacy or between patients in
terms of ADHD subtype, age, gender or previous treat-
ment (TAR, pp. 266f.).
Conclusion
The NICE ADHD health technology assessment does not
provide a complete account of the problem addressed.
From an economic perspective, the omission from analy-
sis of psychosocial interventions, representing a mainstay
of ADHD therapy, is especially disturbing, as estimates of
allocative efficiency require all possible options to be con-
sidered.
Furthermore the literature search was incomplete, existing
evidence was used in an overly restrictive manner, and
neither long-term sequelae nor caregiver burden were
addressed. These shortcomings were confounded by out-
right technical errors, including but not limited to [11] the
apparent confusion of efficacy and effectiveness.
Although the assessment may have its uses in listing exist-
ing literature and presenting condensed summaries, it
leaves substantial room for improvement. Its main con-
clusions rest on shaky grounds and are potentially mis-
leading. NICE itself, in its final appraisal determination
and its guidance issued in March 2006, wisely moderated
the putatively "clear conclusions" of the technology
assessment report [3]. Understandably the appraisal proc-
ess following the assessment was unable to overcome the
limitations of the latter, which on the basis of its restricted
dataset could not address the full range of questions spec-
ified in its scope (cf. Results, above).
Regarding the technology assessment process, the broad
range of observed anomalies can be interpreted as symp-
Structure of the economic model Figure 1
Structure of the economic model. The economic model 
was composed of modules for each product, which had a 
common structure and were combined sequentially to 
reflect "treatment strategies". The structure of the modules 
implied, inter alia, that the withdrawal rates "due to intolera-
ble side-effects" should be independent from "no response" 
to treatment. This requirement was violated because intent-
to-treat analyses were used to estimate withdrawal rates, 
which reported "withdrawals" for many reasons, including 
lack of efficacy, inevitably leading to double-counting of non-
responders (TAR, p. 230). The impact of this phenomenon 
was unevenly distributed across the treatments evaluated 
(TAR, p. 231 and p. 236), resulting in a biased assessment 
[11]. Graphical representation of model reproduced from 
King et al. 2006, with kind permission.Child and Adolescent Psychiatry and Mental Health 2008, 2:1 http://www.capmh.com/content/2/1/1
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toms, which may be indicative of specific underlying
problems. In the present case, such underlying issues
appear likely to have included an insufficient integration
of clinical and economic perspectives, the extraordinarily
high level of standardization of NICE technology apprais-
als, enforcing the computation of clinical outcomes as
quality-adjusted life years and hereby requiring the clini-
cal problem definition to fit to a preconceived solution,
and the apparent absence of effective quality assurance
systems [11]. Beyond avoiding certain technical errors, a
more appropriate evaluation strategy might have made
better use of available data on symptomatic improvement
such as Conners Rating Scale scores, considered the
impact of treatment nonadherence in ADHD, addressed
clinical studies and meta-analyses indicating differences
in effectiveness between stimulants and nonstimulants,
reflected information on the importance of coexisting
conditions and functional impairment, and discussed the
long-term sequelae associated with ADHD [11].
While there remains a need for more research into the
long-term effectiveness and cost-effectiveness of ADHD
treatment strategies [68], at the same time a new, state-of-
the-art systematic review including economic evaluations
would be most welcome.
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